Marian E Major

US Patent:

7074410, Jul 11, 2006

Filed:

Feb 2, 2004

Appl. No.:

10/770117

Inventors:

Jay A. Berzofsky - Bethesda MD, US
Stephen M. Feinstone - Washington DC, US
Marian E. Major - Alexandria VA, US
Pablo Sarobe - Pamplona, ES

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/29
C07H 21/00
C07H 21/04

US Classification:

4241891, 4241841, 4241851, 4241861, 4242051, 4242281, 536 2372

Abstract:

Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

US Patent:

7341726, Mar 11, 2008

Filed:

May 5, 2006

Appl. No.:

11/429670

Inventors:

Jay A. Berzofsky - Bethesda MD, US
Pablo Sarobe - Pamplona, ES
Stephen M. Feinstone - Washington DC, US
Marian E. Major - Alexandria VA, US

Assignee:

The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/29
C07H 21/04
C12N 15/00

US Classification:

4241891, 4241841, 4241851, 4241861, 4242041, 4242281, 4353201, 536 2372

Abstract:

Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

US Patent:

8603468, Dec 10, 2013

Filed:

Nov 4, 2008

Appl. No.:

12/741612

Inventors:

Pei Zhang - Rockville MD, US
Marian Major - Alexandria VA, US
Stephen Feinstone - Washington DC, US

Assignee:

The United States of America, as Represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/395
A01N 1/02

US Classification:

4241301, 435 2, 4241391, 4241471, 4241491

Abstract:

Aspects of the present invention concern compositions that induce and/or improve an immune response to hepatitis C virus (HCV). Methods of making and using compositions that include epitopes of the HCV E2 structural protein involved in promoting or inhibiting neutralization of HCV are provided.

US Patent:

6685944, Feb 3, 2004

Filed:

Oct 19, 2001

Appl. No.:

09/763260

Inventors:

Jay A. Berzofsky - Bethesda MD
C. David Pendleton - Bethesda MD
Stephen M. Feinstone - Washington DC
Marian E. Major - Alexandria VA
Pablo Sarobe - Pamplona, ES

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3929

US Classification:

4241891, 435 5, 435 724, 4353201, 4242281, 514 15, 530327, 530350, 536 2372

Abstract:

The present invention provides 1) an isolated peptide having the amino acid sequence DLMGYIPAV, (SEQ ID NO: 1); 2) an isolated HCV core polypeptide comprising an LâA substitution at amino acid position 139; 3) an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2; and 4) a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. The present invention further provides methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

US Patent:

20150291684, Oct 15, 2015

Filed:

Oct 26, 2012

Appl. No.:

14/437593

Inventors:

Marian Elaine MAJOR - Alexandria VA, US
Alla KACHKO - Rockville MD, US
- Bethesda MD, US
- Koltsovo, RU

International Classification:

C07K 16/10
A61K 39/29
C12N 7/00
A61K 45/06

Abstract:

Novel epitope regions on hepatitis C virus E1E2 glycoprotein that induce a neutralizing antibody response in vivo are identified. Cross-neutralizing monoclonal antibodies that bind specifically to the epitopes are disclosed.

US Patent:

20150118242, Apr 30, 2015

Filed:

May 16, 2013

Appl. No.:

14/401648

Inventors:

- Bethesda MD, US
Stephen M. Feinstone - Washington DC, US
Marian Major - Alexandria VA, US
Pei Zhang - Rockville MD, US

International Classification:

C07K 16/10
G01N 33/576

US Classification:

4241391, 5303873, 4241781, 435 5, 5303879

Abstract:

A specific epitope on the surface of the hepatitis C virus that induces a neutralizing antibody response in vivo and neutralizing monoclonal antibodies that bind specifically to the epitope are disclosed. The antibodies block hepatitis C virus from infecting cells.